Search
01/08/2025
Management of Patients With Multifocal Motor Neuropathy: A Global Quantitative Survey of Neurologists
Querol, L, Lewis, R, Sommer, C, Bromberg, M, Barrera-Sierra, S, Arvin-Berod, C, Nisbet, P, Gelinas, D, Guptill, J, Wood, J. Management of Patients With Multifocal Motor Neuropathy: A Global Quantitative Survey of Neurologists. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30(3)DOI:. PMID:. IF:3.200(Q2/4D).
01/08/2025
Empasiprubart in Multifocal Motor Neuropathy: Exploratory Analyses of the Phase 2 ARDA Study
van der Pol, WL, Krijgsman, D, Querol, L, Persson, E, Rutjens, S, Cadour, S, Dijkxhoorn, K, Bloemenkamp, LM, de Zeeuw, E, Vujcic, M, Van de Walle, I. Empasiprubart in Multifocal Motor Neuropathy: Exploratory Analyses of the Phase 2 ARDA Study. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30(3)DOI:. PMID:. IF:3.200(Q2/4D).
01/08/2025
Test Database and International Collaboration For Improving Peripheral Neurology in Resource Limited Settings
Eric, CT, Querol, L, Rodés, M, Thirugnanam, UN. Test Database and International Collaboration For Improving Peripheral Neurology in Resource Limited Settings. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30(3)DOI:. PMID:. IF:3.200(Q2/4D).
01/08/2025
Impact of Prior Chronic Inflammatory Demyelinating Polyneuropathy Treatments in the ADHERE Trial: Post Hoc Analyses
Allen, J, Lin, J, Stettner, M, Guptill, J, Istas, G, De Roeck, A, Kuwabara, S, Pinter, GL, Querol, L, Suresh, N, Karam, C, Skripuletz, T, Rinaldi, S, Echaniz-Laguna, A, Hewamadduma, C, Van Hoorick, B, Yamasaki, R, van Doorn, P, Lewis, R. Impact of Prior Chronic Inflammatory Demyelinating Polyneuropathy Treatments in the ADHERE Trial: Post Hoc Analyses. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30(3)DOI:. PMID:. IF:3.200(Q2/4D).
01/08/2025
Genetic Modifiers in Hereditary and Wild-Type TTR Amyloidosis: Update on Genome-wide Association Study
Vegezzi, E, Quartesan, I, Facchini, S, Curro, R, Mussinelli, R, Palladini, G, Milani, P, Nuvolone, M, Anan, I, Todorova, A, Tournev, I, Hegenbart, U, Schönland, S, Siepen, F, Gillmore, JD, Razvi, Y, Rowczenio, D, Coelho, T, Lemos, C, Alves-Ferreira, M, Mandich, P, Conceicao, I, Marques, W Jr, Tomaselli, P, Alves, G, Planté-Bordeneuve, V, Perrain, V, Hahn, K, Reilly, MM, Houlden, H, Pons, CC, Morales, M, Fabrizi, GM, Tagliapietra, M, Knoll, K, Trenkwalder, T, Cappelli, F, Argirò, A, Arregui, ALD, Agudo, PI, Torrón, RF, Arana-Achaga, X, Goena-Vives, C, Martinez, MLP, Aguirre, MA, Saez, M, Cisneros-Barroso, E, Luigetti, M, Berk, J, Prokaeva, T, Sekijima, Y, Yoshinaga, T, Garcia, SK, Théaudin, M, Guaraldi, P, Gragera, A, Rojas-García, R, Carbayo-Viejo, A, Gonzalez-Duarte, A, Cardenas-Soto, K, Menao, S, Kleopa, K, Zamba-Papanicolaou, E, Christodoulou, C, Waddington-Cruz, M, Foguel, D, Russo, M, Mazzeo, A, Sevilla, T, Sivera, R, Tasaki, M, Ueda, M, Reisin, R, Cejas, LL, Petit, C, Di Stefano, V, Antonini, G, Leonardi, L, Sanchez-Tejerina, D, Manganelli, F, Tozza, S, Pareyson, D, Fenu, S, Briani, C, Salvalaggio, A, Obici, L, Cortese, A. Genetic Modifiers in Hereditary and Wild-Type TTR Amyloidosis: Update on Genome-wide Association Study. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30(3)DOI:. PMID:. IF:3.200(Q2/4D).
01/06/2025
Safety and efficacy data from the phase 2 ARDA study of empasiprubart in multifocal motor neuropathy
Querol, L, Harbo, T, Peric, S, Hussain, Y, Cadour, S, van de Walle, I, Persson, E, Vujcic, M, van de Steen, O, Allen, J, Orazio, EN, Attarian, S, Karam, C, Katzberg, H, Stettner, M, Rinaldi, S, van der Pol, W. Safety and efficacy data from the phase 2 ARDA study of empasiprubart in multifocal motor neuropathy. EUROPEAN JOURNAL OF NEUROLOGY. 2025; 32DOI:. PMID:. IF:3.900(Q1/3D).
01/06/2025
Safety and efficacy of riliprubart in chronic inflammatory demyelinating polyneuropathy: 76-week phase 2 trial results
Querol, L, Lewis, RA, Hartung, HP, van Doorn, PA, Lin, J, Dionne, A, Attarian, S, Wallstroem, E, Auwarter, K, Lu, Y, Alonso, MA, Atassi, N, Hughes, RAC. Safety and efficacy of riliprubart in chronic inflammatory demyelinating polyneuropathy: 76-week phase 2 trial results. EUROPEAN JOURNAL OF NEUROLOGY. 2025; 32DOI:. PMID:. IF:3.900(Q1/3D).
01/06/2025
Effect of efgartigimod PH20 SC on lower limb function in chronic inflammatory demyelinating polyneuropathy in ADHERE
Rinaldi, S, Allen, J, Lin, J, Stettner, M, Merkies, I, Guptill, J, Hewamadduma, C, Istas, G, De Roeck, A, Kuwabara, S, Lauria, G, Querol, L, Suresh, N, Karam, C, Skripuletz, T, Echaniz-Laguna, A, Van Hoorick, B, Yamasaki, R, Lewis, R, van Doorn, P. Effect of efgartigimod PH20 SC on lower limb function in chronic inflammatory demyelinating polyneuropathy in ADHERE. EUROPEAN JOURNAL OF NEUROLOGY. 2025; 32DOI:. PMID:. IF:3.900(Q1/3D).